Cipla announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The company’s total income reached ₹7,280.82 Crores for the quarter, with a net profit after tax of ₹674.56 Crores. For the nine months period, total income was ₹22,355.24 Crores, and the net profit after tax stood at ₹3,319.68 Crores. The results reflect a solid performance driven by pharmaceutical sales and strategic business initiatives.
Financial Performance Overview
Cipla has released its unaudited consolidated financial results for the third quarter (Q3) of the financial year 2026, ending on December 31, 2025. Key highlights from the report include:
- Total Income: The company reported a total income of ₹7,280.82 Crores for the quarter.
- Net Profit After Tax: Net profit after tax for Q3 stood at ₹674.56 Crores.
The results showcase a resilient business model amidst evolving market conditions. A detailed analysis of the financial performance is provided below.
Nine Months Performance
The cumulative performance for the nine months ending December 31, 2025, demonstrates consistent growth and profitability:
- Total Income: The total income for the nine-month period reached ₹22,355.24 Crores.
- Net Profit After Tax: The net profit after tax for the same period was reported as ₹3,319.68 Crores.
Segment Highlights
The pharmaceutical segment continues to be a strong contributor to Cipla’s revenue. New ventures are also showing promising growth. ₹27.07 Crores was deposited with the NPPA against certain demand notices.
Key Business Developments
Significant business developments during the quarter and subsequent to the quarter include:
- Cipla increased to ₹161.55 Crores paid up equity share capital.
- Acquired 100% stake in Inzpera Healthscience Limited.
- Paid ₹1,107.28 Crores for acquiring perpetual rights to manufacture and market Galvus and Galvus combination brands used in the treatment of type 2 diabetes with effect from January 1, 2026.
Source: BSE
